Celyad Oncology SA CYADY Stock Analysis
- PINK
- Stock
- Market closed · opens Monday 9:30 AM ET
$0.60 unchanged at close Oct 25
Last close · Previous close $0.60
- Market cap
- $13.56MAt the Oct 25 close
- Dividend yield
- NoneLast 12 months
Price chart
$0.60down $0.15, 19.46%Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$0.60Oct 24
- Volume3.01KOct 25 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume9.77KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Oct 25 close. Total return includes reinvested dividends.Price change only, without dividends.
| Period | CYADY |
|---|---|
| Short term | |
| 1M | CYADY: down 19.5% |
| 3M | CYADY: up 27.7% |
| YTD | CYADY: up 21.7% |
| 1Y | CYADY: down 44.4% |
| Long term | |
| 3Y | CYADY: down 92.6% −58.0% a year |
| 5Y | CYADY: down 97.5% −52.2% a year |
$10,000 invested in CYADY 5 years ago (Oct 25, 2018) would be worth about $250 at the close on , with dividends reinvested.
| Period | CYADY |
|---|---|
| Short term | |
| 1M | CYADY: down 19.5% |
| 3M | CYADY: up 27.7% |
| YTD | CYADY: up 21.7% |
| 1Y | CYADY: down 44.4% |
| Long term | |
| 3Y | CYADY: down 92.6% −58.0% a year |
| 5Y | CYADY: down 97.5% −52.2% a year |
$10,000 invested in CYADY 5 years ago (Oct 25, 2018) would be worth about $250 at the close on , not counting dividends.
All-time high
$64.00
Closing high on . Now 99.1% below that record.
Split-adjusted daily closes since Jun 19, 2015.
Stock splits
CYADY hasn’t split since its price history begins in 2015.
Valuation
The Oct 25 close compared with reported results. 12-month figures aren’t available until four quarters are reported. Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
Not available
12-month figures aren’t available until four quarters are reported.
Other valuation measures
- 3.0×Book value as of Dec 31, 2022
Price relative to accounting equity (book value) per share on the Dec 31, 2022 balance sheet. Asset-light companies often trade far above book value.
P/B = Price ÷ Book value per sharePrice-to-book ratio - $675.99KAt the Oct 25 close
What it would cost to buy the whole business: the market cap at the Oct 25 close, plus debt, minus cash and short-term investments from the Dec 31, 2022 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own CYADY DCF in Excel. Value Celyad Oncology SA with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q4 FY22, the quarter ended Dec 31, 2022, and balance-sheet figures are as of Dec 31, 2022. 12-month figures aren’t available until four quarters are reported.
Revenue and net income
12-month figures aren’t available until four quarters are reported.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q4 FY20 (Dec 31, 2020) | Not reported | Not reported | Not reported |
| Q2 FY21 (Jun 30, 2021) | Not reported | Not reported | Not reported |
| Q4 FY21 (Dec 31, 2021) | Not reported | Not reported | Not reported |
| Q2 FY22 (Jun 30, 2022) | Not reported | Not reported | Not reported |
| Q4 FY22 (Dec 31, 2022) | Not reported | Not reported | Not reported |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY20 (Dec 31, 2020) | $6.10K | −$20.98M | −$1.50 |
| FY21 (Dec 31, 2021) | $0.00 | −$30.13M | −$1.93 |
| FY22 (Dec 31, 2022) | $0.00 | −$43.55M | −$1.93 |
Margins
- Gross
- Operating
- Net
The lines show each quarter. What margins tell you
Cash flow
12-month figures aren’t available until four quarters are reported.
Shareholder returns
12-month figures aren’t available until four quarters are reported.
Balance sheet
- $13.24MAs of Dec 31, 2022
Cash plus short- and long-term marketable securities on the Dec 31, 2022 balance sheet.
- Total debt$271.28KAs of Dec 31, 2022
- Net cash$12.97MAs of Dec 31, 2022
- 1.42As of Dec 31, 2022
Current assets divided by current liabilities on the Dec 31, 2022 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.06As of Dec 31, 2022
Total debt divided by shareholders’ equity on the Dec 31, 2022 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
12-month figures aren’t available until four quarters are reported.
About Celyad Oncology SA
Celyad Oncology is a biotechnology company focused on innovative technologies chimeric antigen receptor (CAR) T-cell therapies. The Company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T candidates in solid tumors and hematological malignancies. Celyad Oncology is based in Mont-Saint-Guibert, Belgium and New York, NY.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Belgium
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- PINK
- Asset type
- Common stock
- Price history since
CYADY news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
CYADY stock FAQ
What is CYADY stock’s price today?
Celyad Oncology SA (CYADY) traded at $0.60 at the close on , unchanged from the previous close of $0.60.
If you invested $1,000 in CYADY 5 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in CYADY on would be worth about $25 at the close on , a total return of −97.5%. The same $1,000 would be worth $556 if invested one year ago. Past performance doesn’t predict future returns.
What is Celyad Oncology SA’s market cap?
Celyad Oncology SA’s market capitalization is about $13.6 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $0.60 (how market cap works). Celyad Oncology SA reported 22.59M shares outstanding at the end of its latest quarter ().
Does CYADY pay a dividend?
Celyad Oncology SA hasn’t paid a dividend in the last twelve months.
What is CYADY’s all-time high?
CYADY’s highest closing price was $64.00 on , adjusted for stock splits. At $0.60 at the close on , it is 99.1% below that record.
Has CYADY stock ever split?
No. CYADY hasn’t split since its price history begins in 2015.
How has CYADY stock performed?
Including dividends and measured to the close on , CYADY has returned +21.7% so far this year and −44.4% over the past year, and −97.5% over five years (−52.2% a year). Past performance doesn’t predict future returns.
What sector and industry is Celyad Oncology SA in?
Celyad Oncology SA is in the Healthcare sector and the Biotechnology industry, and is headquartered in Belgium.
What exchange does CYADY trade on?
Celyad Oncology SA trades on the PINK under the ticker symbol CYADY. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.